INDEMNIFICATION AGREEMENTIndemnification Agreement • May 9th, 2018 • Provention Bio, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ____, by and between Provention Bio, Inc., a Delaware corporation (the “Company”), and ____ (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 9th, 2018 • Provention Bio, Inc. • Pharmaceutical preparations • New Jersey
This EMPLOYMENT AGREEMENT (this “Agreement”), dated April 25, 2017 and effective on the date of consummation of the initial closing of the private placement offering of the Company’s Series A Preferred Stock, par value $0.0001 per share (the “Effective Date”), is by and between PROVENTION BIO, Inc., a Delaware corporation (the “Company”) and ASHLEIGH PALMER (the “Executive”).
PROVENTION BIO, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 9th, 2018 • Provention Bio, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of April 25, 2017, is made and entered into by and between PROVENTION BIO, INC., a Delaware corporation with its principal executive offices located at 110 Old Driftway Lane, Lebanon, NJ 08833 (the “Company”), and each of the purchasers listed on Schedule A hereto (the “Purchasers”).
Re: Engagement AgreementLetter Agreement • May 9th, 2018 • Provention Bio, Inc. • Pharmaceutical preparations • New York
This letter agreement (the “Agreement”) confirms the terms and conditions that will govern the Provention Bio, Inc., a Delaware corporation (together with its affiliates, subsidiaries, predecessors, and successors, the “Company”), engagement (the “Engagement”) of MDB Capital Group, LLC (together with its affiliates, “MDB”) as the Company’s exclusive financial advisor and placement agent in connection with an offering or series of offerings of Company securities.
EMPLOYMENT AGREEMENTEmployment Agreement • May 9th, 2018 • Provention Bio, Inc. • Pharmaceutical preparations • New Jersey
This EMPLOYMENT AGREEMENT (this “Agreement”), dated April 25, 2017 and effective on the date of consummation of the initial closing of the private placement offering of the Company’s Series A Preferred Stock, par value $0.0001 per share, is by and between PROVENTION BIO, Inc., a Delaware corporation (the “Company”) and FRANCISCO LEON (the “Executive”).
LICENSE AGREEMENT by and between VACTECH OY and PROVENTION BIO, INC.License Agreement • May 9th, 2018 • Provention Bio, Inc. • Pharmaceutical preparations • Delaware
This License Agreement (“Agreement”), effective as of April 25, 2017 (the “Effective Date”), is made by and between Vactech oy, a corporation organized and existing under the laws of Finland (“Vactech”), and Provention Bio, inc., a corporation organized and existing under the laws of the State of Delaware (“Provention”).
CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been omitted pursuant to a request for confidential treatment and, where applicable, have been marked with an asterisk (“[*****]”) to denote where omissions have been made. The...Confidential Treatment Requested • May 9th, 2018 • Provention Bio, Inc. • Pharmaceutical preparations • Delaware
This license, development, and commercialization agreement is effective as of the last date of execution by the parties hereto (“Effective Date”) and is between Janssen Sciences Ireland UC, a company organized under the laws of Ireland, having offices at EastGate Village, EastGate, Little Island, Co, Cork, Ireland (“Licensor”) and Provention Bio, Inc., a Delaware company with its principal offices at 110 Old Driftway Lane, Lebanon, New Jersey 08833 (“Licensee” or “Provention”).
PROVENTION BIO, INC. VOTING AGREEMENTAdoption Agreement • May 9th, 2018 • Provention Bio, Inc. • Pharmaceutical preparations • Delaware
This Voting Agreement (the “Agreement”) is made and entered into as of April 25, 2017, by and among PROVENTION BIO, INC., a Delaware corporation (the “Company”), and certain holders of the Company’s Series A Preferred Stock, $0.0001 par value per share (the “Preferred Stock”) listed on the Schedule of Investors attached as Schedule A hereto (together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Subsections 11.8 or 11.9 below, the “Investors”), and those certain holders of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) listed on the Schedule of Key Holders attached as Schedule B hereto (together with any subsequent shareholders, or any transferees, who become parties hereto as “Key Holders” pursuant to Subsections 11.8 or 11.9 below, the “Key Holders”). Each of the Investors and the Key Holders are individually referred to herein as a “Shareholder” and are collectively referred to herein as the “Shareho
Provention Bio, Inc. Lock-Up AGREEMENTLock-Up Agreement • May 9th, 2018 • Provention Bio, Inc. • Pharmaceutical preparations • Delaware
